344 related articles for article (PubMed ID: 33865350)
1. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Spagnolo F; Boutros A; Cecchi F; Croce E; Tanda ET; Queirolo P
BMC Cancer; 2021 Apr; 21(1):425. PubMed ID: 33865350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
4. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.
Wei Y; Li Y; Du Q; Peng X; Jin J; Guo H; Li Y; Li Q
J Immunol Res; 2020; 2020():5269787. PubMed ID: 33381603
[TBL] [Abstract][Full Text] [Related]
5. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
6. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Beaver JA; Hazarika M; Mulkey F; Mushti S; Chen H; He K; Sridhara R; Goldberg KB; Chuk MK; Chi DC; Chang J; Barone A; Balasubramaniam S; Blumenthal GM; Keegan P; Pazdur R; Theoret MR
Lancet Oncol; 2018 Feb; 19(2):229-239. PubMed ID: 29361469
[TBL] [Abstract][Full Text] [Related]
7. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Barroso-Sousa R; Tolaney SM
Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
[TBL] [Abstract][Full Text] [Related]
8. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
10. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Guo X; Li W; Hu J; Zhu EC; Su Q
Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
[TBL] [Abstract][Full Text] [Related]
12. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
16. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.
Landre T; Des Guetz G; Chouahnia K; Fossey-Diaz V; Culine S
Drugs Aging; 2020 Oct; 37(10):747-754. PubMed ID: 32681403
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
Yao Q; Gu L; Su R; Chen B; Cao H
J Cell Mol Med; 2020 Nov; 24(22):13494-13506. PubMed ID: 33078904
[TBL] [Abstract][Full Text] [Related]
19. An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers.
Liu M; Gao Y; Yuan Y; Shi S; Wu J; Tian J; Zhang J
Biomed Pharmacother; 2021 Nov; 143():112238. PubMed ID: 34649362
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]